BioCryst Pharmaceuticals has been granted a patent for compounds that inhibit plasma kallikrein, which can be used in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity. The patent also covers pharmaceutical compositions containing these compounds. GlobalData’s report on BioCryst Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights BioCryst Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on BioCryst Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. BioCryst Pharmaceuticals's grant share as of September 2023 was 37%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11708332B2) discloses a compound and its pharmaceutical compositions for the treatment of diseases or conditions characterized by unwanted plasma kallikrein activity. The compound has a specific structure, and the pharmaceutical compositions can be formulated for parenteral or oral administration.

The patent claims describe a compound with a specific structure, which can be used to treat diseases or conditions characterized by unwanted plasma kallikrein activity. The compound can be in the form of a pharmaceutically acceptable salt, such as a hydrochloride salt or a bis(hydrochloride) salt.

The patent also covers pharmaceutical compositions containing the compound. These compositions can be formulated for parenteral administration, which involves injecting the composition into the body, or for oral administration, which involves taking the composition by mouth.

Furthermore, the patent claims a method of treating a disease or condition characterized by unwanted plasma kallikrein activity by administering the pharmaceutical composition containing the compound to a subject in need. The method can involve using the compound in the form of a pharmaceutically acceptable salt, such as a hydrochloride salt or a bis(hydrochloride) salt. The method can also involve administering the pharmaceutical composition through parenteral or oral administration.

The diseases or conditions that can be treated using the compound and its pharmaceutical compositions include stroke, inflammation, reperfusion injury, acute myocardial infarction, deep vein thrombosis, angina, edema, angioedema, hereditary angioedema, sepsis, arthritis, hemorrhage, inflammatory bowel disease, diabetes mellitus, retinopathy, diabetic retinopathy, diabetic macular edema, diabetic macular degeneration, age-related macular edema, age-related macular degeneration, proliferative retinopathy, neuropathy, hypertension, brain edema, increased albumin excretion, macroalbuminuria, and nephropathy.

In particular, the method of treating a disease or condition characterized by unwanted plasma kallikrein activity can be specifically applied to angioedema and hereditary angioedema.

Overall, this granted patent provides a compound and its pharmaceutical compositions for the treatment of diseases or conditions characterized by unwanted plasma kallikrein activity, offering potential therapeutic options for a wide range of medical conditions.

To know more about GlobalData’s detailed insights on BioCryst Pharmaceuticals, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies